Kazuko Nakashima-Kaneda

Suita, 5650871, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Flavonoid Interactions with Renal Organic Anion Transporters OAT1 and OAT3: Structure-Activity Relationships and Clinical Implications.

Flavonoid Interactions with Renal Organic Anion Transporters OAT1 and OAT3: Structure-Activity Relationships and Clinical Implications.

Journal: International journal of molecular sciences

Published: March 10, 2026

Enhanced tumor retention of the novel LAT1-targeting PET probe [18F]FAMT-OMe: A comparative study with [18F]FAMT in glioma mouse models.

Enhanced tumor retention of the novel LAT1-targeting PET probe [18F]FAMT-OMe: A comparative study with [18F]FAMT in glioma mouse models.

Journal: Nuclear medicine and biology

Published: November 30, 2025

Astatine-211-Labeled Therapy Targeting Amino Acid Transporters: Overcoming Drug Resistance in Non-Small Cell Lung Cancer.

Astatine-211-Labeled Therapy Targeting Amino Acid Transporters: Overcoming Drug Resistance in Non-Small Cell Lung Cancer.

Journal: International journal of molecular sciences

Published: August 27, 2025

LAT1-Targeted Alpha Therapy Using 211At-AAMT for Bone and Soft Tissue Sarcomas.

LAT1-Targeted Alpha Therapy Using 211At-AAMT for Bone and Soft Tissue Sarcomas.

Journal: International journal of molecular sciences

Published: August 01, 2025

L-3-[18F]-Fluoro-α-Methyl Tyrosine as a PET Tracer for Tumor Diagnosis: A Systematic Review from Mechanisms to Clinical Applications.

L-3-[18F]-Fluoro-α-Methyl Tyrosine as a PET Tracer for Tumor Diagnosis: A Systematic Review from Mechanisms to Clinical Applications.

Journal: International journal of molecular sciences

Published: March 01, 2025

Development of LAT1-Selective Nuclear Medicine Therapeutics Using Astatine-211.

Development of LAT1-Selective Nuclear Medicine Therapeutics Using Astatine-211.

Journal: International journal of molecular sciences

Published: October 27, 2024

Comparison Length of Linker in Compound for Nuclear Medicine Targeting Fibroblast Activation Protein as Molecular Target.

Comparison Length of Linker in Compound for Nuclear Medicine Targeting Fibroblast Activation Protein as Molecular Target.

Journal: International journal of molecular sciences

Published: October 27, 2024

Evaluation of Targeted Alpha Therapy Using [211At]FAPI1 in Triple-Negative Breast Cancer Xenograft Models.

Evaluation of Targeted Alpha Therapy Using [211At]FAPI1 in Triple-Negative Breast Cancer Xenograft Models.

Journal: International journal of molecular sciences

Published: September 14, 2024

Preclinical Evaluation of Biodistribution and Toxicity of [211At]PSMA-5 in Mice and Primates for the Targeted Alpha Therapy against Prostate Cancer.

Preclinical Evaluation of Biodistribution and Toxicity of [211At]PSMA-5 in Mice and Primates for the Targeted Alpha Therapy against Prostate Cancer.

Journal: International journal of molecular sciences

Published: April 17, 2024

Comparison of Nuclear Medicine Therapeutics Targeting PSMA among Alpha-Emitting Nuclides.

Comparison of Nuclear Medicine Therapeutics Targeting PSMA among Alpha-Emitting Nuclides.

Journal: International journal of molecular sciences

Published: November 30, 2023

Inhibition of cancer-type amino acid transporter LAT1 suppresses B16-F10 melanoma metastasis in mouse models.

Inhibition of cancer-type amino acid transporter LAT1 suppresses B16-F10 melanoma metastasis in mouse models.

Journal: Scientific reports

Published: April 19, 2023

Evaluation of Astatine-211-Labeled Fibroblast Activation Protein Inhibitor (FAPI): Comparison of Different Linkers with Polyethylene Glycol and Piperazine.

Evaluation of Astatine-211-Labeled Fibroblast Activation Protein Inhibitor (FAPI): Comparison of Different Linkers with Polyethylene Glycol and Piperazine.

Journal: International journal of molecular sciences

Published: March 30, 2023

Showing 1-12 of 27

Last Updated: 09/26/2026